- FUJIFILM Corporation has invested in Austrian biotechnology company VALANX Biotech to support the development of antibody-drug conjugate (ADC) manufacturing technologies.
- The collaboration aims to strengthen Fujifilm’s CDMO capabilities in ADC development and contract manufacturing.
FUJIFILM Corporation has announced an investment in VALANX Biotech, a biotechnology company based in Vienna, Austria, that develops manufacturing technologies for antibody-drug conjugates (ADCs). The investment is being made through Fujifilm’s corporate venture capital activities in life sciences and is intended to strengthen the company’s contract development and manufacturing organization (CDMO) capabilities in the ADC field.
The collaboration will focus on VALANX’s proprietary Golden Site™ Technology, which enables site-specific conjugation by incorporating synthetic amino acids into antibodies. According to the companies, the technology is designed to improve the control of conjugation sites and the drug-to-antibody ratio in ADCs, potentially improving product uniformity and stability.
Fujifilm stated that ADCs are a key focus modality for its biopharmaceutical contract manufacturing strategy. The company is building an integrated platform that spans multiple stages of ADC production, including antibody development, linker and payload manufacturing, conjugation, and formulation.
Under this strategy, Fujifilm plans to begin offering fully integrated ADC manufacturing services in Japan at FUJIFILM Toyama Chemical in 2027. The facility is intended to serve as a hub for future global expansion of the company’s ADC contract manufacturing operations.
The company said that strategic investments and partnerships with technology developers such as VALANX are part of its broader effort to expand manufacturing capabilities for next-generation biopharmaceuticals and support pharmaceutical and biotechnology partners developing innovative therapies.
